192 patients screened

- Exclusion due to age or
cytologic, anatomo-
pathologic, medical or social
criteria

49 patients enrolled

- Drop out at visit A or B (10 for
progression to HSIL, 11 for
negativation, 4 for colposcopic
criteria, 9 for no high risk HPV)

15 patients treated and in follow-up

Randomization

- 10 GM-CSF
- 5 placebo

Figure 1
Figure 2

(a) CPM

- KN
- HaCat
- CK2
- SiHa
- CasKi
- KT1F4

- Control
- GM-CSF

(b) Ki67 index

- Placebo
- GM-CSF

- A or B
- D
- F

visits

Figure 2
Figure 3
Figure 4
Figure 5

(a) Graph showing the percentage of IFN-γ+ cells for different groups (G4, G5, G10) across visits A to F, with subplots for CD8, CD4, and NK cells.

(b) Graph similar to (a) but with a different scale and data presentation.

(c) Graph showing anti-HPV16 Ab titers for groups G4, G5, and G10 across visits BT to F.

(d) Graph showing anti-HPV31 Ab titers for groups G4 and P1 across visits BT to F.

Legend:
- G4
- G5
- G10
- CD8
- CD4
- NK
- GM-CSF treatment

Visit:
- A
- B
- C
- D
- E
- F

Anti-VLP: HP16 Ab titer
- BT
- E
- F

Anti-VLP: HP31 Ab titer
- BT
- E
- F